Pfizer Inc (NYSE:PFE) | Pfizer Announces Positive Top-Line Results From Phase 3 Study Of NONACOG ALFA (BeneFIX®) Once-Weekly Prophylaxis For Hemophilia B

[at noodls] – Pfizer Inc. (NYSE:PFE) today announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX ® Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand treatment . . . → Read More: Pfizer Inc (NYSE:PFE) | Pfizer Announces Positive Top-Line Results From Phase 3 Study Of NONACOG ALFA (BeneFIX®) Once-Weekly Prophylaxis For Hemophilia B Similar Articles: Market Update: Pfizer Inc (NYSE:PFE) – Pfizer Announces Submission of Biologics License Application to the FDA for Investigational Meningococcal B Vaccine Market Update: Pfizer Inc (NYSE:PFE) – AstraZeneca rejects Pfizer’s raised bid of $106 bln Market Update (NYSE:PFE): Pfizer prepares sweeter bid for AstraZeneca – report